Photosensitizing antibody-fluorophore conjugates
The present disclosure relates to compositions and methods of killing cells. In particular examples, the method includes contacting a cell having a cell surface protein with a therapeutically effective amount of an antibody-IR700 molecule, wherein the antibody specifically binds to the cell surface protein, such as a tumor-specific antigen on the surface of a tumor cell. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm at a dose of at least 1 J cm −2 . The cell is also contacted with one or more therapeutic agents (such as an anti-cancer agent), for example about 0 to 8 hours after irradiating the cell, thereby killing the cell. Also provided are methods of imaging cell killing in real time, using fluorescence lifetime imaging. Also provided are wearable devices that include an article of clothing, jewelry, or covering; and an NIR LED incorporated into the article, which can be used with the disclosed methods.
1. A phototoxic pharmaceutical composition for treating a tumor expressing HER1, comprising:
a phototoxic conjugate comprising an IR700 molecule conjugated to an antibody that binds HER1; and
a pharmaceutical carrier, wherein the phototoxic conjugate exhibits phototoxicity to kill tumor cells expressing HER1.
2. The pharmaceutical composition of claim 1 , wherein the antibody is selected from the group consisting of cetuximab, zalutumumab, nimotuzumab and matuzumab, or an antigen binding fragment thereof.
3. The pharmaceutical composition of claim 1 , wherein the antibody is cetuximab.
4. The pharmaceutical composition of claim 1 , wherein the antibody is zalutumumab.
5. The pharmaceutical composition of claim 1 , wherein the antibody is nimotuzumab.
6. The pharmaceutical composition of claim 1 , wherein the antibody is matuzumab.
7. A combination, comprising:
a first pharmaceutical composition comprising a phototoxic conjugate comprising an IR700 molecule conjugated to an antibody that binds HER1, wherein the phototoxic conjugate exhibits phototoxicity to kill tumor cells expressing HER1; and
a second pharmaceutical composition comprising an additional therapeutic agent.
8. The combination of claim 7 , wherein the first and/or second composition comprise a pharmaceutically acceptable carrier.
9. The combination of claim 7 , wherein the antibody is selected from the group consisting of cetuximab, zalutumumab, nimotuzumab and matuzumab, or an antigen binding fragment thereof.
10. The combination of claim 7 , wherein the antibody is cetuximab.
11. The combination of claim 7 , wherein the antibody is zalutumumab.
12. The combination of claim 7 , wherein the antibody is nimotuzumab.
13. The combination of claim 7 , wherein the antibody is matuzumab.
14. The combination of claim 7 , wherein the first and second pharmaceutical composition are formulated separately.
15. The combination of claim 7 , wherein the therapeutic agent is an anti-cancer or anti-neoplastic agent.
16. The combination of claim 7 , wherein the therapeutic agent is selected from the group consisting of a radiotherapeutic agent, a chemotherapeutic agent, an antibiotic, an alkylating agent, an antioxidant and a kinase inhibitor.
17. The combination of claim 7 , wherein the therapeutic agent is selected from among a microtubule binding agent, a DNA intercalator or cross-linker, a DNA synthesis inhibitor, a DNA or RNA transcription inhibitor, an antibody, an enzyme, an enzyme inhibitor and a compound that affects gene regulation.
18. The combination of claim 7 , wherein the therapeutic agent is selected from among paclitaxel, docetaxel, vinblastine, vindesine, vinorelbine, epothilone, colchicine, dolastatin 15, nocodazole, podophyllotoxin, rhizoxin, actinomycin D, daunorubicin, cisplatin, carboplatin, oxaliplatin, mitomycin C, bleomycin, chlorambucil, cyclophosphamide, methotrexate, 5-fluro-5′-deoxyuridine, 5-fluorouracil, camptothecin, etopo side, formestane, trichostatin, raloxifene, 5-azacytidine, 5-aza-2′-deoxycytidine, tamoxifen, 4-hydroxytamoxifen, mifepristone, imatinib, gefitinib, erlotinib, adriamycine, apigenin, rapamycine, zebularine, cimetidine, interleukin-2 (IL-2), and an anti-CTLA4 antibody or an antigen binding fragment thereof.